Review



rabbit anti cd133 polyclonal abs  (Biorbyt)


Bioz Verified Symbol Biorbyt is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Biorbyt rabbit anti cd133 polyclonal abs
    Cytoplasmic and membranous <t>CD133</t> expression in epithelial cells of the colonic crypts. (a) Minimal, week expression (sum score 0) in mice of control negative group. (b) Focal, weak expression (sum score 1) in control positive group. (c) Focal, weak-moderate expression (sum score 4) deeply within the colonic crypt in group 3 (DSS exposure & 6-TG treatment). (d) Diffuse, weak expression (sum score 3) in group 4 (DSS exposure & 10 mg/kg b.w. Shogaol treatment). (e) and (f) Diffuse, moderate expression (sum score 6) extends into the transient amplifying and apical regions of the colonic crypts in group 5 (DSS exposure & 20 mg/kg b.w. Shogaol treatment) and group 6 (DSS exposure & 40 mg/kg b.w. Shogaol treatment), respectively.
    Rabbit Anti Cd133 Polyclonal Abs, supplied by Biorbyt, used in various techniques. Bioz Stars score: 94/100, based on 66 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+anti+cd133+polyclonal+abs/CD133+antibody/pmc06431407-58-18-27
    Average 94 stars, based on 66 article reviews
    rabbit anti cd133 polyclonal abs - by Bioz Stars, 2026-10
    94/100 stars

    Images

    1) Product Images from "Effect of Shogaol on the Expression of Intestinal Stem Cell Markers in Experimentally Induced Colitis in BALB/c Mice"

    Article Title: Effect of Shogaol on the Expression of Intestinal Stem Cell Markers in Experimentally Induced Colitis in BALB/c Mice

    Journal: Analytical Cellular Pathology (Amsterdam)

    doi: 10.1155/2019/5134156

    Cytoplasmic and membranous CD133 expression in epithelial cells of the colonic crypts. (a) Minimal, week expression (sum score 0) in mice of control negative group. (b) Focal, weak expression (sum score 1) in control positive group. (c) Focal, weak-moderate expression (sum score 4) deeply within the colonic crypt in group 3 (DSS exposure & 6-TG treatment). (d) Diffuse, weak expression (sum score 3) in group 4 (DSS exposure & 10 mg/kg b.w. Shogaol treatment). (e) and (f) Diffuse, moderate expression (sum score 6) extends into the transient amplifying and apical regions of the colonic crypts in group 5 (DSS exposure & 20 mg/kg b.w. Shogaol treatment) and group 6 (DSS exposure & 40 mg/kg b.w. Shogaol treatment), respectively.
    Figure Legend Snippet: Cytoplasmic and membranous CD133 expression in epithelial cells of the colonic crypts. (a) Minimal, week expression (sum score 0) in mice of control negative group. (b) Focal, weak expression (sum score 1) in control positive group. (c) Focal, weak-moderate expression (sum score 4) deeply within the colonic crypt in group 3 (DSS exposure & 6-TG treatment). (d) Diffuse, weak expression (sum score 3) in group 4 (DSS exposure & 10 mg/kg b.w. Shogaol treatment). (e) and (f) Diffuse, moderate expression (sum score 6) extends into the transient amplifying and apical regions of the colonic crypts in group 5 (DSS exposure & 20 mg/kg b.w. Shogaol treatment) and group 6 (DSS exposure & 40 mg/kg b.w. Shogaol treatment), respectively.

    Techniques Used: Expressing, Control

    Immunofluorescence expression of the CD133 protein in the cytoplasm of the colonic cryptal epithelium. (a) and (b) Weak (+) expression in mice of the control negative and control positive group. (c) and (d) Weak-moderate (+ to ++) expression in the in deep portions of the colonic crypts in mice of group 3 (6-TG treatment) and group 4 (10 mg/kg b.w. Shogaol treatment). (e) and (f) Moderate (++) expression in mice of group 5 (20 mg/kg b.w. Shogaol treatment) and mice of group 6 (40 mg/kg b.w. Shogaol treatment).
    Figure Legend Snippet: Immunofluorescence expression of the CD133 protein in the cytoplasm of the colonic cryptal epithelium. (a) and (b) Weak (+) expression in mice of the control negative and control positive group. (c) and (d) Weak-moderate (+ to ++) expression in the in deep portions of the colonic crypts in mice of group 3 (6-TG treatment) and group 4 (10 mg/kg b.w. Shogaol treatment). (e) and (f) Moderate (++) expression in mice of group 5 (20 mg/kg b.w. Shogaol treatment) and mice of group 6 (40 mg/kg b.w. Shogaol treatment).

    Techniques Used: Immunofluorescence, Expressing, Control

    Related Articles

    Incubation:

    Article Title: Effect of Shogaol on the Expression of Intestinal Stem Cell Markers in Experimentally Induced Colitis in BALB/c Mice
    Article Snippet: .. Following that, the slides were divided into 2 sets: the first set was incubated overnight at 4°C with rabbit anti-CD133 polyclonal Abs (1 : 100, San Francisco Biorbyt, USA), and the second set was incubated with rabbit anti-CD34 monoclonal Abs (1 : 100, Dako, Germany). ..



    Similar Products

    rabbit anti cd133 polyclonal abs  (Biorbyt)
    94
    Biorbyt rabbit anti cd133 polyclonal abs
    Cytoplasmic and membranous <t>CD133</t> expression in epithelial cells of the colonic crypts. (a) Minimal, week expression (sum score 0) in mice of control negative group. (b) Focal, weak expression (sum score 1) in control positive group. (c) Focal, weak-moderate expression (sum score 4) deeply within the colonic crypt in group 3 (DSS exposure & 6-TG treatment). (d) Diffuse, weak expression (sum score 3) in group 4 (DSS exposure & 10 mg/kg b.w. Shogaol treatment). (e) and (f) Diffuse, moderate expression (sum score 6) extends into the transient amplifying and apical regions of the colonic crypts in group 5 (DSS exposure & 20 mg/kg b.w. Shogaol treatment) and group 6 (DSS exposure & 40 mg/kg b.w. Shogaol treatment), respectively.
    Rabbit Anti Cd133 Polyclonal Abs, supplied by Biorbyt, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+anti+cd133+polyclonal+abs/CD133+antibody/pmc06431407-58-18-27
    Average 94 stars, based on 1 article reviews
    rabbit anti cd133 polyclonal abs - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    rabbit anti human polyclonal cd133  (Bioss)
    95
    Bioss rabbit anti human polyclonal cd133
    Cytoplasmic and membranous <t>CD133</t> expression in epithelial cells of the colonic crypts. (a) Minimal, week expression (sum score 0) in mice of control negative group. (b) Focal, weak expression (sum score 1) in control positive group. (c) Focal, weak-moderate expression (sum score 4) deeply within the colonic crypt in group 3 (DSS exposure & 6-TG treatment). (d) Diffuse, weak expression (sum score 3) in group 4 (DSS exposure & 10 mg/kg b.w. Shogaol treatment). (e) and (f) Diffuse, moderate expression (sum score 6) extends into the transient amplifying and apical regions of the colonic crypts in group 5 (DSS exposure & 20 mg/kg b.w. Shogaol treatment) and group 6 (DSS exposure & 40 mg/kg b.w. Shogaol treatment), respectively.
    Rabbit Anti Human Polyclonal Cd133, supplied by Bioss, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+anti+cd133+polyclonal+abs/Rabbit+Anti-Human+IgGF(ab')2+Antibody/10__1097_slash_cji__0000000000000086-47-7-13
    Average 95 stars, based on 1 article reviews
    rabbit anti human polyclonal cd133 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    Cytoplasmic and membranous CD133 expression in epithelial cells of the colonic crypts. (a) Minimal, week expression (sum score 0) in mice of control negative group. (b) Focal, weak expression (sum score 1) in control positive group. (c) Focal, weak-moderate expression (sum score 4) deeply within the colonic crypt in group 3 (DSS exposure & 6-TG treatment). (d) Diffuse, weak expression (sum score 3) in group 4 (DSS exposure & 10 mg/kg b.w. Shogaol treatment). (e) and (f) Diffuse, moderate expression (sum score 6) extends into the transient amplifying and apical regions of the colonic crypts in group 5 (DSS exposure & 20 mg/kg b.w. Shogaol treatment) and group 6 (DSS exposure & 40 mg/kg b.w. Shogaol treatment), respectively.

    Journal: Analytical Cellular Pathology (Amsterdam)

    Article Title: Effect of Shogaol on the Expression of Intestinal Stem Cell Markers in Experimentally Induced Colitis in BALB/c Mice

    doi: 10.1155/2019/5134156

    Figure Lengend Snippet: Cytoplasmic and membranous CD133 expression in epithelial cells of the colonic crypts. (a) Minimal, week expression (sum score 0) in mice of control negative group. (b) Focal, weak expression (sum score 1) in control positive group. (c) Focal, weak-moderate expression (sum score 4) deeply within the colonic crypt in group 3 (DSS exposure & 6-TG treatment). (d) Diffuse, weak expression (sum score 3) in group 4 (DSS exposure & 10 mg/kg b.w. Shogaol treatment). (e) and (f) Diffuse, moderate expression (sum score 6) extends into the transient amplifying and apical regions of the colonic crypts in group 5 (DSS exposure & 20 mg/kg b.w. Shogaol treatment) and group 6 (DSS exposure & 40 mg/kg b.w. Shogaol treatment), respectively.

    Article Snippet: Following that, the slides were divided into 2 sets: the first set was incubated overnight at 4°C with rabbit anti-CD133 polyclonal Abs (1 : 100, San Francisco Biorbyt, USA), and the second set was incubated with rabbit anti-CD34 monoclonal Abs (1 : 100, Dako, Germany).

    Techniques: Expressing, Control

    Immunofluorescence expression of the CD133 protein in the cytoplasm of the colonic cryptal epithelium. (a) and (b) Weak (+) expression in mice of the control negative and control positive group. (c) and (d) Weak-moderate (+ to ++) expression in the in deep portions of the colonic crypts in mice of group 3 (6-TG treatment) and group 4 (10 mg/kg b.w. Shogaol treatment). (e) and (f) Moderate (++) expression in mice of group 5 (20 mg/kg b.w. Shogaol treatment) and mice of group 6 (40 mg/kg b.w. Shogaol treatment).

    Journal: Analytical Cellular Pathology (Amsterdam)

    Article Title: Effect of Shogaol on the Expression of Intestinal Stem Cell Markers in Experimentally Induced Colitis in BALB/c Mice

    doi: 10.1155/2019/5134156

    Figure Lengend Snippet: Immunofluorescence expression of the CD133 protein in the cytoplasm of the colonic cryptal epithelium. (a) and (b) Weak (+) expression in mice of the control negative and control positive group. (c) and (d) Weak-moderate (+ to ++) expression in the in deep portions of the colonic crypts in mice of group 3 (6-TG treatment) and group 4 (10 mg/kg b.w. Shogaol treatment). (e) and (f) Moderate (++) expression in mice of group 5 (20 mg/kg b.w. Shogaol treatment) and mice of group 6 (40 mg/kg b.w. Shogaol treatment).

    Article Snippet: Following that, the slides were divided into 2 sets: the first set was incubated overnight at 4°C with rabbit anti-CD133 polyclonal Abs (1 : 100, San Francisco Biorbyt, USA), and the second set was incubated with rabbit anti-CD34 monoclonal Abs (1 : 100, Dako, Germany).

    Techniques: Immunofluorescence, Expressing, Control